AbCellera Biologics Inc. (ABCL), established in 2012, is a leading technology company specializing in the fastest identification of antibody-producing cells during responses to immunization or infection. The Vancouver-based company aims to revolutionize drug discovery through its extensive, proprietary platforms leveraging the power of AI, genomics, and microfluidics.
AbCellera's main focus revolves around creating a database of immune system responses that could be instrumental in the development of new therapies and drugs. Central to this task is the deployment of the proprietary Pandemic Prevention Platform (P3), a program funded by the US Defense Advanced Research Projects Agency (DARPA), for rapid identification of potent antiviral antibodies. AbCellera surpassed traditional boundaries in the field of biotech, most notedly in 2020 when they developed Bamlanivimab, a treatment for COVID-19, in partnership with Eli Lilly, within a record timeframe of just 90 days from genetic sequence to drug selection.
Voted 'Life Sciences Company of the Year', AbCellera has successfully collaborated with pharmaceutical giants such as Gilead Sciences, Pfizer, Merck & Co., and Eli Lilly, delivering the best-in-class technology and therapeutics. The company went public in December 2020, listing on the Nasdaq Stock Market under the symbol “ABCL”, raising $556 million in one of the biggest Initial Public Offerings (IPOs) in Canadian history.
AbCellera's advanced AI-powered platform characterizes and analyzes antibody-producing cells to uncover molecules with the desired biological function. This paves the way for faster and more efficient drug development, significantly decreasing the time consumed in traditional methods.
AbCellera's unusual approach to setting a new standard in the sector has positioned it as a trailblazer. By continuously evolving and fine-tuning its state-of-the-art technology, the firm encapsulates the spirit of innovation and progress. Its work has substantial real-world implications; by driving cutting-edge research and ensuring quicker access to necessary drugs, it paves the path to formidable advancements in the fields of biotech and healthcare.
AbCellera ultimately forms the crucial intersection where technology and biology meet, improving patient outcomes, and shaping the future of drug discovery. Despite its relative infancy, the firm has markedly impacted the biotech industry, symbolizing a new paradigm in antibody discovery and establishing a cornerstone in rapid drug development, as reflected in its response to the COVID-19 pandemic.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
AbCellera Biologics (ABCL) is gaining attention following positive Phase 2 results for ABCL635, an antibody targeting vasomotor symptoms in postmenopausal women. Despite recent short-term volatility, the stock has shown significant positive momentum over the last 90 days and year-to-date, trading at a discount to the average analyst target. The company's transition to a clinical-stage biotech focusing on internal programs and the potential market opportunity for ABCL635 are key factors in its current "undervalued" narrative.
UBS has initiated coverage on AbCellera Biologics (ABCL) with a "Buy" rating and set an $18 price target. The company currently holds an average "buy" rating among analysts, with a mean price target of $16.82. The full article content is behind a premium paywall.
AbCellera Biologics experienced a 125% stock climb over the past year despite a significant revenue drop and wider losses, reflecting a split investor narrative. The bullish view focused on clinical pipeline advancements, particularly ABCL635, while bears highlighted financial volatility and execution risks. The current stock price of US$12.63 now reflects a narrative betting on milestone and royalty-driven income from clinical programs.